Second-generation AR inhibitors, PARP inhibitors, and PSMA-targeted agents significantly improve survival, while immunotherapies like checkpoint inhibitors and vaccines rekindle anti-tumor immunity. This evidence concerns the gene FOLH1 and neoplasm.